

Health Based Guidance for Groundwater Health Risk Assessment Unit, Environmental Health Division 651-201-4899

> Web Publication Date September 25, 2009 Expiration Date: September 2014

Chemical Name: Perfluorohexane sulfonate

CAS: 108427-53-8 (anion) 355-46-4 (acid)

Synonyms: PFHxS, Perfluorohexane sulfonic acid, Perfluorohexane-1-sulphonic acid

A single whole animal toxicity study has been conducted for PFHxS. This study, conducted in rats, consists of a combined repeated dose toxicity study with a reproduction/developmental toxicity screening test. Limited toxicokinetic (e.g., half-life information) is also available in rats. Based on the results of the toxicity study, PFHxS exposure resulted in decreases in body weight and cholesterol levels and an increase in prothrombin time at an estimated human equivalent dose that is similar to the human equivalent dose that formed the basis of the chronic RfD and HRL for PFOS. Sensitive effects observed following PFOS exposure included decreased body weight, cholesterol levels and thyroid hormone levels as well as developmental delays and increased liver weight and histological changes. The PFHxS toxicity study did not include thyroid hormone analysis, however, microscopic changes in the thyroid at higher dose levels were reported. Although no reproductive or developmental effects were reported it should be noted that because of the selectivity of the endpoints and the short duration (approximately 40 days) the reproductive/developmental screening assessment does not provide definitive evidence of no reproductive or developmental effects. After a careful review of the available toxicological information, staff have determined that they are unable to recommend risk assessment advice (RAA) for PFHxS based on the limited data currently available.

Acute Noncancer Risk Assessment Advice  $(nRAA_{acute}) = Not Derived (Insufficient Data)$ 

**Short-term Noncancer Risk Assessment Advice (nRAA**short-term) = **Not Derived (Insufficient Data)** 

**Subchronic Noncancer Risk Assessment Advice (nRAA**<sub>subchronic</sub>) = **Not Derived (Insufficient Data)** 

**Chronic Noncancer Risk Assessment Advice (nRAA**chronic) = Not Derived (Insufficient Data)

**Cancer Risk Assessment Advice (cRAA) = Not Applicable** 

Cancer classification: PFHxS has not been classified as to carcinogenic potential.

Slope factor: NA

**Volatile:** Yes (moderate)

## **Summary of changes since 1993/1994 HRL promulgation:**

None.

## Summary of toxicity testing for health effects identified in the Health Standards Statute:

	Endocrine	Immunotoxicity	Development	Reproductive	Neurotoxicity
Tested?	Sec. Observations <sup>1</sup>	No	Yes <sup>2</sup>	Yes <sup>3</sup>	Yes <sup>4</sup>
Effects?	-	-	No	No	No

Note: Even if testing for a specific health effect was not conducted for this chemical, information about that effect might be available from studies conducted for other purposes. Most chemicals have been subject to multiple studies in which researchers identify a dose where no effects were observed, and the lowest dose that caused one or more effects. A toxicity value based on the effect observed at the lowest dose across all available studies is considered protective of all other effects that occur at higher doses.

## **Comments on extent of testing or effects:**

- <sup>1</sup> No in vivo studies. Secondary observations treatment related microscopic changes in the thyroid were observed following exposure to > 3 mg/kg-d PFHxS. However, more sensitive parameters (e.g., serum thyroid hormone levels) were not measured. Alternations in thyroid hormone levels have been observed following treatment with other PFCs. The results of an in vitro study evaluating PFCs ability to compete with thyroxin (T4) for binding to the human thyroid hormone transport protein transthyretin (TTR) indicate that PFHxS has the ability to compete with T4 for binding to TTR.
- <sup>2</sup> A single screening level assessment has been conducted. No treatment effects on development were reported at dose levels up to 10 mg/kg-d. Although the results of this study indicate that development is not a sensitive endpoint the selectivity of the endpoints and the short duration the screening assessment does not provide definitive evidence of no developmental effects.
- <sup>3</sup> A single screening level assessment has been conducted. No treatment effects on male or female reproductive ability were reported at dose levels up to 10 mg/kg-d. Males were exposed 14 days prior to mating and through study day 42-44. Females were exposed 14 days prior to mating, throughout gestation and lactation (postnatal day 22). Although the results of this study indicate that the reproductive system is not a sensitive endpoint selectivity of the endpoints and the short duration of the screening assessment does not provide definitive evidence of no reproductive effects.
- <sup>4</sup> Functional observation battery and motor activity assessments were conducted as part of the toxicological evaluation in the single toxicity study available. No effects were observed at dose levels up to 10 mg/kg-d.

## **References:**

3M 2003. Environmental and Health Assessment of Perfluorooctane Sulfonic Acid and Its Salts.

ATSDR (Agency for Toxic Substances and Disease Registry). Minimal Risk Levels. <a href="http://www.atsdr.cdc.gov/mrls.html">http://www.atsdr.cdc.gov/mrls.html</a>

ATSDR 2009. Draft Toxicological Profile for Perfluoroalkyls. May 2009

Australian Government, Department of Health and Aging, National Industrial Chemicals Notification and Assessment Scheme (NICNAS) 2005. Existing Chemical Hazard Assessment Report Potassium Perfluorobutane Sulfonate.

Benskin JP, AO De Silva, LH Martin, F Arsenault, R McCrindle, N Riddell, SA Mabury, JW Martin. 2009. Disposition of Perfluorinated Acid Isomers in Sprague-Dawley Rats: Part 1: Single Dose. Env Tox Chem 28(3) in press.

Butenhoff et al, Perfluorooctane Sulfonate-Induced Perinatal Mortality in Rat Pups is Associated with a Steep Dose-Response. The Toxicologist 66(1): 25 (Abstract 120), 2002.

Butenhoff JL. Personal communication: PFHxS OCED 422 Study Overview. September 17, 2007.

Butenhoff JL, DJ Ehresman, SC Chang, GA Parker, DG Stump. 2009a. Gestational and lactational exposure to potassium perfluorooctanesulfonate (K<sup>+</sup>PFOS) in rats: Developmental neurotoxicity. Repro Tox 27:319-330.

Butenhoff JL, SC Chang, DJ Ehresman, RG York. 2009b. Evaluation of Potential Reproductive and Developmental Toxicity of Potassium Perfluorohexanesulfonate in Sprague Dawley Rats. Repro Tox 27:331-341.

Butenhoff JL. Personal communication: PFHxS Pharmacokinetics. August 12, 2009c.

Calafat AM, LY Wong, Z Kuklenyik, JA Reidy, LL Needham. 2007. Polyfluoroalkyl Chemicals in the U.S. Population: Data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and Comparison with NHANES 1999-2000. Env Health Perspec. 115(11)1596-1602.

California Environmental Protection Agency, OEHHA Toxicity Criteria Database. <a href="http://www.oehha.ca.gov/risk/ChemicalDB/index.asp;http://www.oehha.ca.gov/risk/pdf/cancerpotalpha810">http://www.oehha.ca.gov/risk/ChemicalDB/index.asp;http://www.oehha.ca.gov/risk/pdf/cancerpotalpha810</a> <a href="http://www.oehha.ca.gov/risk/pdf/cancerpotalpha810">05.pdf</a>

Chang SC, Ehresman DJ, Bjork JA, Wallace KB, Parker GA, Stump DG, Butenhoff JL. 2009. Gestational and Lactational Exposure to Potassium Perfluorooctanesulfonate (K+PFOS) in Rats: Toxicokinetics, Thyroid Hormone Status, and Related Gene Expression, Repro Tox 27:387-399.

Ehresman DJ, S Chang, JA Bjork, JA Hart, PH Lieder, KB Wallace, & JL Butenhoff 2007. Increased Acyl CoA Oxidase Activity in Rats After Five Consecutive Doses of Perfluorobutanesulfonate, Perfluorohexanesulfonate, and Perfluorooctanesulfonate. Abstract #865. The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 96, Number S-1, March 2007.

Environmental Protection Agency. Health Effects Assessment Summary Tables (HEAST). July 1997.

Environmental Protection Agency. Integrated Risk Information System.

Environmental Protection Agency. Office of Drinking Water. Drinking Water Standards and Health Advisories (August, 2006) <a href="http://www.epa.gov/waterscience/criteria/drinking/dwstandards.pdf">http://www.epa.gov/waterscience/criteria/drinking/dwstandards.pdf</a>

Environmental Protection Agency Region 3. Risk Based Concentration. (click on RBC Tables PDF link) <a href="http://www.epa.gov/reg3hwmd/risk/human/rbc/rbc1006.pdf">http://www.epa.gov/reg3hwmd/risk/human/rbc/rbc1006.pdf</a>

Environmental Protection Agency Region 9. Preliminary Remediation Goal. (click on Region 9 PRGs 2004 Table link) <a href="http://www.epa.gov/region09/waste/sfund/prg/files/04prgtable.pdf">http://www.epa.gov/region09/waste/sfund/prg/files/04prgtable.pdf</a>

Ericson, I, M Gomez, M Nadal, B van Baval, G Lindstrom, JL Domingo. 2007. Perfluorinated chemicals in blood of residents in Catalonia (Spain) in relation to age and gender: A pilot study. Env Int 33:616-623.

Ericson I, R Marti-Cid, M Nadal, R Van Bavel, G Lindstrom, JL Domingo. 2008a. Human Exposure to Perfluorinated Chemicals through the Diet: Intake of Perfluorinated Compounds in Foods from the Catalan (Spain) Market. J Agric Food Chem 56:1787-1794.

Ericson I, M Nadal, B van Bavel, G Lindstrom, JL Domingo 2008b. Levels of perfluorochemicals in water samples from Catalonia, Spain: is drinking water a significant contribution to human exposure? Env Sci Pollut Res 15:614-619.

Falandysz et al 2006. Is fish a major source of fluorinated surfactants and repellants in humans living on the Baltic Coast? Environmental Science and Technology 40(3):748-751.

Fromme H, M Schlummer, A Moller, L Gruber, G Wolz, J Ungewiss, S Bohmer, W Dekant, R Mayer, B Liebl, D Twardella. 2007. Exposure of an Adult Population to Perfluorinated Substances Using Duplicate Diet Portions and Biomonitoring Data. Environ Sci Technol 41:7928-7933.

Gordon SC, S Schurch, M Amrein, M Schoel. 2007. Effects of Perfluorinated Acids on Pulmonary Surfactant Properties in vitro. Abstract #437. The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 96, Number S-1, March 2007.

Hickey NJ, D Crump, SP Jones, SW Kennedy. 2009. Effects of eighteen perfluoroalkyl compounds (PFCs) on mRNA expression in chick embryo hepatocyte cultures. Tox Sci. Advance Access. July 17, 2009

Hoberman AM and RG York, R. G. (2003). Oral (gavage) combined repeated dose toxicity study of T–7706 with the reproduction/developmental toxicity screening test. 3M Sponsor Study Number T–7706.1. US EPA Administrative Record, AR-226-1523.

Holzer J, O Midasch, K Rauchfuss, M Kraft, R Reupert, J Angerer, P Kleeschulte, N Marschall, M Wilhelm. 2008. Biomonitoring of Perfluorinated Compounds in Children and Adults Exposed to Perfluorocatanoate-Contaminated Drinking Water. Env Health Perspec 116(5):651-657.

International Agency for Research on Cancer (IARC). Agents Reviewed by the IARC Monographs. <a href="http://monographs.iarc.fr/ENG/Classification/Listagentsalphorder.pdf">http://monographs.iarc.fr/ENG/Classification/Listagentsalphorder.pdf</a>

Interstate Technology and Regulatory Council (ITRC). 2017. Naming Conventions and Physical and Chemical Properties of Per- and Polyfluoroalkyl Substances (PFAS). <a href="http://pfas-1.itrcweb.org/wp-content/uploads/2017/10/pfas\_fact\_sheet\_naming\_conventions\_11\_13\_17.pdf">http://pfas-1.itrcweb.org/wp-content/uploads/2017/10/pfas\_fact\_sheet\_naming\_conventions\_11\_13\_17.pdf</a>. Accessed February 6, 2018.

Karrman A, KH Harada, K Inoue, T Takasuga, E Ohi, A Koizumi. 2009. Relationship between dietary exposure and serum perfluorochemical (PFC) levels - A case study. Environ Int doi:10.1016/j.envint.2009.01.010

Lau, et al., 2003. Exposure to Perfluorooctane Sulfonate during Pregnancy in Rat and Mouse. II. Postnatal Evaluations. Tox Sci 74: 382-392.

Lieder, P. H., Noker, P. E., Gorman, G. S., Tanaka, S. C., and Butenhoff, J. L. (2006b). Elimination pharmacokinetics of a series of perfluorinated alkyl carboxylates and sulfonates (C4, C6 and C8) in male and female Cynomolgus monkeys. Eur. Soc. Environ. Toxicol. Chem. (abstract 297).

Luebker, D. et al., Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. Toxicology 215:126-148, 2005a.

Luebker, D. et al., Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: Dose-response, and biochemical and pharmacokinetic parameters. Toxicology 215:149-169, 2005b.

Minnesota Department of Health (MDH) 2009. East Metro Perfluorochemical Biomonitoring Pilot Project. http://www.health.state.mn.us/divs/eh/tracking/finalpfcrpt.pdf

Oak Ridge National Laboratory. Screening Levels for Chemical Contaminants. <a href="http://epa-prgs.ornl.gov/chemicals/download.shtml">http://epa-prgs.ornl.gov/chemicals/download.shtml</a>

Olsen GW, JM Burris, DJ Ehresman, JW Froehlich, AM Seacate, JL Butenhoff, LR Zobel. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Env Hlth Persp 115:1298-1305, 2007

Olsen GW, SC Chang, PE Noker, GS Gorman, DJ Ehresman, PH Lieder, JL Butenhoff. 2009. A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys and humans. Toxicology 256:65-74.

Organization for Economic Co-operation and Development (OECD) Nov. 21, 2002. Hazard Assessment of Perfluorooctane Sulfonate (PFOS) and Its Salts. <a href="http://www.oecd.org/document/58/0,2340,en\_2649\_37465\_2384378\_1\_1\_1\_37465,00.html#3">http://www.oecd.org/document/58/0,2340,en\_2649\_37465\_2384378\_1\_1\_1\_37465,00.html#3</a> (Accessed Nov. 2002)

Seacat et al., Subchronic Toxicity Studies on Perfluorooctanesulfonate Potassium Salt in Cynomolgus Monkeys. Tox Sci 68:249-264, 2002

Spliethoff HM, L Tao, SM Shaver, KM Aldous, KA Pass, K Kannan, GA Eadon. 2008. Use of Newborn Screening Program Blood Spots for Exposure Assessment: Declining Levels of Perfluorinated Compounds in new York State Infants. Env Sci Tech 42:5361-5367.

Sundstrom M, JA Hart, SC Chang, DJ Ehresman, GS Gorman, PE Noker, GW Olsen, A Bergman, JL Butenhoff. 2009. Comparative Pharmacokinetics of Perfluorohexanesulfonate (PFHxS) in Rats and Monkeys. DIOXIN 2009.

Syracuse Research PhysProp Database. <a href="http://www.syrres.com/esc/physdemo.htm">http://www.syrres.com/esc/physdemo.htm</a>

Takacs M and BD Abbott. 2007. Activation of mouse and human peroxisome proliferator-activated receptor alpha (PPARα) by perfluoroalkyl acids (PFAAs) investigated using a trans-activation model in Cos-1 cells. Abstract #1424. The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 96, Number S-1, March 2007

Tao L, K Kannan, CM Wong, KF Arcaro, JL Butenhoff. 2008. Perfluorinated Compounds in Human Milk from Massachusetts, U.S.A. Environ Sci Technol. Advance Access published March 7, 2008: 10.1021/es702789k

Thibodeaux, et al., Exposure to Perfluorooctane Sulfonate during Pregnancy in Rat and Mouse. I. Maternal and Prenatal Evaluations. Tox Sci 74: 369-381, 2003.

Tomas LML, AM Calafat, K Kato, J Thompson, F Harden, P Hobson, A Sjodin, JF Mueller. 2009. Polyfluoroalkyl Chemicals in Pooled Blood Serum from Infants, Children and Adults in Australia. Environ. Sci. Tech. 43:4194-4199.

Weiss J, PL Andersson, MH Lamoree, PEG Leonards, SPJ van Leeuwen, T Hamers. 2009. Competitive Binding of Poly- and Perfluorinated Compounds to the Thyroid Hormone Transport Protein Transthyretin. Tox Sci 109(2)206-216.

Wolf CJ, ML Takacs, JE Schmid, C Lau, BD Abbott. 2008. Activation of Mouse and Human Peroxisome Proliferator – Activated Receptro Alpha by Perfluoroalkyl Acids of Different Functional Groups and Chain Lengths. Tox Sci 106(1)162-171.

World Health Organization (WHO) Recommended Classification of Pesticides by Hazard. 2004. <a href="http://www.who.int/ipcs/publications/pesticides\_hazard\_rev\_3.pdf">http://www.who.int/ipcs/publications/pesticides\_hazard\_rev\_3.pdf</a>

World Health Organization. Guidelines for Drinking-Water Quality. Chapter 12 Chemical Fact Sheets. http://www.who.int/water\_sanitation\_health/dwq/gdwq0506\_12.pdf